Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

PHASE1TerminatedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

June 1, 2023

Study Completion Date

June 1, 2023

Conditions
MUC17-positive Solid Tumors
Interventions
DRUG

AMG 199

AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.

Trial Locations (21)

5020

Landeskrankenhaus Salzburg, Salzburg

10002

National Taiwan University Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

20246

Universitaetsklinikum Hamburg Eppendorf Onkologisches Zentrum, Hamburg

27157

Wake Forest University Health Sciences, Winston-Salem

46010

Hospital Clinico Universitario de Valencia, Valencia

81377

Klinikum der Universitaet Muenchen Campus Grosshadern, München

81675

Klinikum rechts der Isar, München

91010

City of Hope National Medical Center, Duarte

92868

University of California at Irvine Medical Center, Orange

94805

Institut Gustave Roussy, Villejuif

04103

Universitaetsklinikum Leipzig, Leipzig

464-8681

Aichi Cancer Center, Nagoya

277-8577

National Cancer Center Hospital East, Kashiwa-shi

104-0045

National Cancer Center Hospital, Chuo-ku

1081 HV

Amsterdam UMC - location VUmc, Amsterdam

2333 ZA

Leids Universitair Medisch Centrum, Leiden

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital Yonsei University Health System, Seoul

138-736

Asan Medical Center, Seoul

08035

Hospital Universitari Vall d Hebron, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY